HER2-positive locally advanced/metastatic gastric and/or gastroesophageal junction (GEJ) adenocarcinoma in Russia

Study identifier:D133HR00028

ClinicalTrials.gov identifier:NCT05892926

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A multicenter observational retrospective study of therapeutic approaches and clinical outcomes in real clinical practice in Russian patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced/metastatic gastric and/or gastroesophageal junction (GEJ) adenocarcinoma

Medical condition

adenocarcinoma

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

200

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 30 May 2023
Estimated Primary Completion Date: 31 May 2024
Estimated Study Completion Date: 31 May 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria